UPDATED INFORMATION of : Masitinib Treatment FOR Progressive Multiple Sclerosis

AB Science SA (Paris:AB)(NYSE-Euronext-FR0010557264-AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis. The article, ‘Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study’, is freely accessible online from BioMed Central’s peer-reviewed journal BMCNeurology (http://www.biomedcentral.com/1471-2377/12/36/abstract).

•Phase 2 study establishes proof-of-concept that oral masitinib has potential therapeutic benefits in patients with progressive forms of multiple sclerosis

•Overall, results add new scientific data to the important question of the potential role of anti inflammatory agents in the management of progressive multiple sclerosis

•A phase 3 study has been initiated based upon these promising results

..

 Please note that all comments are moderated.